Scarica l'app Stockscreener
32.14
0.50%
-0.16
Dopo l'orario di chiusura:
32.14
Alto Neuroscience Inc Borsa (ANRO) Ultime notizie
Alto Neuroscience (ANRO) Reports Another Quarterly Loss, Is The Stock Already Overvalued? - Yahoo Finance
Are Alto Neuroscience’s (ANRO) Rising Losses Funding a Stronger Depression Pipeline or Diluting Discipline? - Yahoo Finance
Alto Neuroscience (ANRO) Stock Looks Stretched On Expanded ALTO 207 Plans - Yahoo Finance
Why Alto Neuroscience (ANRO) Is Up 13.5% After Expanding ALTO-207 Phase 3 And Securing New Funding - Sahm
ANRO Stock Falls After Hours On Failed Schizophrenia Study Results - Stocktwits
Alto Neuroscience (NYSE:ANRO) Upgraded to "Sell" at Wall Street Zen - MarketBeat
Alto Neuroscience (ANRO) investor group discloses 9.99% ownership cap - Stock Titan
Vestal Point Capital (ANRO) discloses 785,000-share Alto Neuroscience position in 13G/A - Stock Titan
BofA Securities Maintains Alto Neuroscience(ANRO.US) With Buy Rating - moomoo.com
Alto Neuroscience (NYSE:ANRO) Stock Price Down 4.7%Here's Why - MarketBeat
Alto Neuroscience, Inc. Stock 12‑Month Price Target Raised to $37.56, Implies 16% Upside - TradingView
Sirenia Capital (ANRO) discloses 2.22M Alto Neuroscience shares under beneficial ownership - Stock Titan
BofA Adjusts Price Target on Alto Neuroscience to $37 From $33 - marketscreener.com
Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO) and Owlet (OWLT) - The Globe and Mail
Alto Neuroscience stock hits all-time high at 32.74 USD By Investing.com - Investing.com Australia
Alto Neuroscience stock hits all-time high at 32.74 USD - Investing.com
Jefferies Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Raises Target Price to $40 - Moomoo
Alto Neuroscience (NYSE:ANRO) Trading 8% Higher Following Earnings Beat - MarketBeat
Alto Neuroscience, Inc. Stock 12‑Month Price Target Raised to $37.11, Implies 27% Upside - TradingView
Wedbush Forecasts Strong Price Appreciation for Alto Neuroscience (NYSE:ANRO) Stock - MarketBeat
Alto Neuroscience (NYSE:ANRO) Stock Price Expected to Rise, BTIG Research Analyst Says - MarketBeat
Biotech Stocks At 52-Week HighsBIVI +22%, XNCR, ANRO, HAE, ACAD - RTTNews
Alto Neuroscience, Inc. Stock 12‑Month Price Target Raised to $36.89, Implies 26% Upside - TradingView
Alto Neuroscience Q2 EPS beats estimates; completes $100M financing - scanx.trade
Alto Neuroscience (NYSE:ANRO) Announces Quarterly Earnings Results - MarketBeat
Alto Neuroscience (ANRO) boosts cash to $243.7M as R&D spend surges - Stock Titan
Alto Neuroscience Reports Q2 Loss As ALTO-207 Program Expands - Quiver Quantitative
Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Business Wire
Alto Neuroscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Alto Neuroscience (NYSE:ANRO) Sets New 52-Week HighShould You Buy? - MarketBeat
Alto Neuroscience (ANRO) Earnings Date and Reports 2026 - MarketBeat
Alto Neuroscience Escapes Investor Drug Trial Suit, For Now - Law360
Alto Neuroscience Inc (ANRO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Shareholders SueWallSt in New Class Action Against Alto Neuroscience, Inc.Act Now - The National Law Review
Alto Neuroscience stock hits all-time high at 29.34 USD By Investing.com - Investing.com Australia
Alto Neuroscience (NYSE:ANRO) Sets New 12-Month HighShould You Buy? - MarketBeat
Alto Neuroscience stock hits all-time high at 29.34 USD - Investing.com
Alto Neuroscience (ANRO) Projected to Announce Earnings on Wednesday - MarketBeat
Recover Investment Losses: Levi & Korsinsky Files Class Action Against Alto Neuroscience, Inc. (ANRO) - The National Law Review
Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Alto Neuroscience: Buy ALTO-207 Advancement TRD And Other Expansion Indications (ANRO) - Seeking Alpha
Perceptive Advisors LLC Buys 225,500 Shares of Alto Neuroscience, Inc. $ANRO - MarketBeat
BlackRock, Inc. Expands Stake in Alto Neuroscience Inc (ANRO) wi - GuruFocus
Alto Neuroscience Inc (ANRO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ANRO|Alto Neuroscience Inc|Price:27.910|Chg%:+1.130 - TradingKey
BlackRock (ANRO) discloses 6.0% beneficial ownership in Alto Neuroscience common stock - Stock Titan
ANRO|Alto Neuroscience Inc|Price:27.350|Chg%:+0.570 - TradingKey
Alto Neuroscience Inc (ANRO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Alto Neuroscience Inc (ANRO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Alto Neuroscience Inc (ANRO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Alto Neuroscience Inc. (ANRO) Gains Momentum: Approaching Key ResistanceSmall Cap Breakouts - dars.gov.et
Alto Neuroscience Inc (ANRO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ANRO|Alto Neuroscience Inc|Price:26.780|Chg%:-0.080 - TradingKey
Alto Neuroscience Inc (ANRO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Alto Neuroscience Inc (ANRO) Institutional Confidence - TradingKey
TradingKey - TradingKey
Affinity Asset Advisors LLC Makes New Investment in Alto Neuroscience, Inc. $ANRO - MarketBeat
Alto Neuroscience, Inc. Revenue Breakdown – NYSE:ANRO - TradingView
Alto Neuroscience (NYSE:ANRO) Rating Lowered to Strong Sell at Zacks Research - MarketBeat
Jennison Associates LLC Buys New Shares in Alto Neuroscience, Inc. $ANRO - MarketBeat
EcoR1 Capital discloses 5.8% Alto Neuroscience (ANRO) stake in Schedule 13G - Stock Titan
Alto Neuroscience (NYSE:ANRO) Rating Increased to Sell at Wall Street Zen - MarketBeat
Alto Neuroscience Raises Capital to Advance ALTO-207 - TipRanks
Alto Neuroscience Announces $3.7 Million Underwritten Offering of Common Stock on NYSE - Minichart
Form 424B5 Alto Neuroscience Inc For: 14 July By Investing.com - Investing.com Nigeria
Alto Neuroscience (NYSE: ANRO) sells 3,776,436 shares at $26.48 - Stock Titan
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):